Compare Gilead Sciences, Inc. (GILD) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kaltura Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Kaltura Inc trades at $1.32 (market cap $202.89M). The key difference: Gilead Sciences, Inc. is far larger — about 897.5× Kaltura Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kaltura Inc for 21 Days on average.
| GILD | KLTR | |
|---|---|---|
Market Cap | $182.09B | $202.89M |
Volume | 4,960,247 | 214,400 |
Sector | Health | Technology |
52-Week High | $155.80 | $1.89 |
52-Week Low | $116.74 | $1.08 |
Typical Hold Time | 111 Days | 21 Days |
Enterprise Value | $205.15B | $215.11M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Kaltura (KLTR) trades at $1.33, up 3.91% with recent earnings beats but negative profitability. Technical indicators show bearish momentum while fundamentals reveal improving margins despite net losses. The company is gaining industry recognition for AI-powered video platforms and secured major partnerships, though cash flow remains negative.
Investment outlook balances AI innovation potential against persistent financial challenges. While analyst sentiment leans positive with 44% buy ratings, high valuation multiples and negative ROE present significant risks. The stock offers speculative appeal for investors betting on AI-driven turnaround despite current unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
